HVHuy Van

Huy Van

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Huy Van has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nghiên cứu hiệu quả cắt polyp đại tràng nhỏ hơn hoặc bằng 10 mm bằng phương pháp thòng lọng lạnh

    by Thị Bích Thủy Hồ, Văn Huy Trần, Đức Thông Nguyễn

    Đặt vấn đề: Cắt polyp đại tràng qua nội soi là phương pháp hiệu quả nhất phòng ngừa ung thư đại tràng. Cắt polyp đại tràng bằng dao điện: kinh điển, hiệu quả, nhưng có thể có các biến chứng chảy máu, thủng sớm hoặc muộn và sót polyp. Để hạn chế những biến chứng này, trên thế giới có nhiều nghiên cứu đề xuất cắt polyp không cuống có kích thước < 10 mm bằng thòng lọng lạnh (không dùng điện khi cắt).Mục tiêu: Đánh giá tỷ lệ thành công của cắt polyp đại tràng ≤ 10 mm bằng phương pháp thòng lọng lạnh qua nội soi. Khảo sát các biến chứng của kỹ thuật này và một số yếu tố liên quan.Đối tượng và phương pháp nghiên cứu: Nghiên cứu so sánh trên 96 bệnh nhân nội soi đại tràng có polyp kích thước ≤ 10 mm, chia ngẫu nhiên thành hai nhóm được cắt polyp qua nội soi bằng thòng lọng lạnh (CSP) và thòng lọng nóng (HSP). Kết quả: Cắt polyp hoàn toàn gặp (94,5%), kết quả cắt polyp hoàn toàn chiếm tỷ lệ cao hơn ở nhóm CSP (95,8% so với HSP 93,8%) (p > 0,05); cụ thể, tỷ lệ cắt hoàn toàn polyp có kích thước < 5 mm, 5 - 8 mm và 9 - 10 mm lần lượt là 100%; 95,9 và 83,3% (p > 0,05). Biến chứng chảy máu sớm gặp 3,1% (4,2% nhóm CSP so với 2,1% nhóm HSP), 1 trường hợp chảy máu muộn ở nhóm HSP (2,1%).Kết luận: CSP hoặc HSP có thể được sử dụng an toàn như một trong những kỹ thuật tiêu chuẩn để cắt bỏ polyp đại trực tràng 4 - 10 mm.

  • Open Access

    Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infections

    by Zihui Wei, Fiona Angrisano, Emily M Eriksson, Ramin Mazhari, Huy Van, Shuning Zheng, Rob J Center, Irene Boo, James McMahon, Jillian Lau, et al.

    Current serological tests cannot differentiate between total immunoglobulin A (IgA) and dimeric IgA (dIgA) associated with mucosal immunity. Here, we describe two new assays, dIgA‐ELISA and dIgA‐multiplex bead assay (MBA), that utilize the preferential binding of dIgA to a chimeric form of secretory component, allowing the differentiation between dIgA and monomeric IgA. dIgA responses elicited through severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection were measured in (i) a longitudinal panel, consisting of 74 samples (n = 20 individuals) from hospitalized cases of coronavirus disease 2019 (COVID‐19); (ii) a longitudinal panel, consisting of 96 samples (n = 10 individuals) from individuals with mild COVID‐19; (iii) a cross‐sectional panel with PCR‐confirmed SARS‐CoV‐2 infection with mild COVID‐19 (n = 199) and (iv) pre–COVID‐19 samples (n = 200). The dIgA‐ELISA and dIgA‐MBA demonstrated a specificity for dIgA of 99% and 98.5%, respectively. Analysis of dIgA responses in the longitudinal panels revealed that 70% (ELISA) and 50% (MBA) of patients elicited a dIgA response by day 20 after PCR diagnosis with a SARS‐CoV‐2 infection. Individuals with mild COVID‐19 displayed increased levels of dIgA within the first 3 weeks after diagnosis but responses appeared to be short lived, compared with sustained IgA levels. However, in samples from hospitalized patients with COVID‐19 we observed high and sustained levels of dIgA, up to 245 days after PCR diagnosis. Our results suggest that severe COVID‐19 infections are associated with sustained levels of plasma dIgA compared with mild cases.


  • Open Access

    A novel point-of-care test for cirrhosis based on dimeric to monomeric IgA ratio in blood: a pilot cohort study

    by Jessica Howell, Huy Van, Minh D. Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Steven Bloom, Avik Majumdar, et al.

    Background and Aims: Dimeric IgA to monomeric IgA ratio (dIgA ratio) is a biomarker of gut mucosal leakage in liver cirrhosis. We evaluated the diagnostic performance of a novel point-of-care (POC) dIgA ratio test for cirrhosis. Methods: Plasma samples from people with chronic liver disease were analyzed using the BioPoint POC dIgA ratio antigen immunoassay lateral flow test. Cirrhosis was defined by Fibroscan>12.5 kPa, clinical evidence of cirrhosis or liver histopathology. POC dIgA test diagnostic accuracy was determined in a test cohort using receiver operating characteristic curve analysis; optimal cutoffs for sensitivity and specificity were then applied to a validation cohort. Results: A total of 1478 plasma samples from 866 patients with chronic liver disease were included (test cohort n = 260, validation cohort n = 606). In all, 32% had cirrhosis; 44% Child-Pugh A, 26% Child-Pugh B, and 29% Child-Pugh C. Median POC dIgA ratio was higher in cirrhosis (0.9) compared with no cirrhosis (0.4, p < 0.001), and in Child-Pugh class B/C compared with A cirrhosis (1.4 Child-Pugh B/C vs. 0.6 Child-Pugh A, p < 0.001). POC dIgA ratio test had good diagnostic accuracy for liver cirrhosis in the test cohort (area under the receiver operating characteristic curve=0.80); a dIgA ratio cutoff of 0.6 had a sensitivity of 74% and specificity of 86%. POC dIgA test accuracy was moderate in the validation cohort (area under the receiver operating characteristic curve=0.75; positive predictive value 64%, negative predictive value 83%). Using a dual cutoff approach, 79% of cirrhosis cases were correctly diagnosed and further testing was avoided in 57%. Conclusions: POC dIgA ratio test had moderate accuracy for cirrhosis. Further studies evaluating the accuracy of POC dIgA ratio testing for cirrhosis screening are warranted. Export


  • Open Access

    The X-ray crystal structure of the N-terminal domain of Ssr4, a Schizosaccharomyces pombe chromatin-remodelling protein

    by Janet Newman, Tom Nebl, Huy Van, Thomas S. Peat

    Ssr4 is a yeast protein from Schizosaccharomyces pombe and is an essential part of the chromatin-remodelling [SWI/SNF and RSC (remodelling the structure of chromatin)] complexes found in S. pombe. These complexes (or their homologues) regulate gene expression in eukaryotic organisms, affecting a large number of genes both positively and negatively. The downstream effects are seen in development, and in humans have implications for disease such as cancer. The chromatin structure is altered by modifying the DNA–histone contacts, thus opening up or closing down sections of DNA to specific transcription factors that regulate the transcription of genes. The Ssr4 sequence has little homology to other sequences in the Protein Data Bank, so the structure was solved using an iodine derivative with SAD phasing. The structure of the N-terminal domain is an antiparallel β-sheet of seven strands with α-helices on one side and random coil on the other. The structure is significantly different to deposited structures and was used as a target in the most recent Critical Assessment of Techniques for Protein Structure Prediction (CASP; https://predictioncenter.org/) competition.